B-cell activating factor belonging to tumour
necrosis factor family (BAFF) is essential for B-cell survival and function through interaction with its receptors
BAFF receptor 3 (BR3),
B-cell maturation antigen (
BCMA) and/or transmembrane activator and
calcium modulator and
cyclophilin ligand interactor (TACI), though
BCMA and/or TACI can also bind to a proliferation-inducing
ligand (APRIL). We evaluate the correlation of the expressions of these
ligands/receptors with different clinical manifestations of
systemic lupus erythematosus (SLE). Levels of BAFF and APRIL in plasma from 73 SLE patients were determined by
enzyme-linked
immunosorbent assay. Expressions of BR3, TACI and
BCMA on CD19+ B cells were detected by flow cytometry. Clinical data were collected and disease activity was evaluated using SLEDAI-2000. SLE patients had elevated BAFF and APRIL levels in their plasma. BAFF levels correlated positively with SLEDAI while negatively with the BR3
protein expression on CD19+ B cells (p < .05). The detected BR3
protein expression in SLE patients was reduced on CD19+
IgD+CD27-, CD19+
IgD+CD27+ as well as CD19+IgD-CD27+ B cells compared to the counterparts of healthy controls (p < .001), whereas SLE patients did not differ from healthy controls in BR3
mRNA levels. In untreated new-onset patients, the expression rate of BR3 on CD19+ B cells correlated negatively with SLEDAI (p < .05). Elevation of BAFF and reduction of BR3 on CD19+ B cells were more obvious in those with
lupus nephritis (LN, p < .05). TACI expression on CD19+ B cells was up-regulated only in those subjects with LN (p < .05). Elevated plasma BAFF and reduced BR3
protein expression on peripheral B cells could act as
biomarkers for active disease in SLE patients. High expression of TACI may indicate the occurrence of LN.